Pharmacotherapeutics in the Critically Ill COVID-19 Patients
- Author:
Wan Rahiza Wan Mat
1
;
Cheah Saw Kian
1
;
Aliza Mohamad Yusof
1
;
Lau Chee Lan
2
;
Michelle Tan Hwee Peng
2
;
Petrick Periyasamy
3
Author Information
- Publication Type:Review
- Keywords: Drug therapy, COVID-19, Critically ill, Steroids, Monoclonal antibody
- From:Malaysian Journal of Medicine and Health Sciences 2022;18(No.1):316-323
- CountryMalaysia
- Language:English
- Abstract: Pharmacotherapeutics are being repurposed and used as off-label at various stages of COVID-19 infection. Clinical trials are being initiated or are ongoing to investigate the effectiveness and safety of these pharmacotherapeutics. This review article outlines the current pharmacotherapeutics and the controversies surrounding their use. The pharmacotherapeutics that were discussed are hydroxychloroquine, favipiravir, lopinavir/ritonavir, remdesivir, interferons, tocilizumab, and steroids. We also discussed the special consideration for pharmacotherapeutics in COVID-19 infection. No pharmacotherapeutics have been found to be effective and approved for the treatment of COVID-19 infection. However, there are clinical trials that have eliminated the possibilities of use of some pharmacotherapeutics while others had shown promising preliminary results of its use
- Full text:11.2022my1213.pdf
